Metropolis Healt

Metropolis Healthcare delivered a strong Q3 FY25, with revenue growing 10.9% year-on-year to INR 323 crores, primarily driven by a 4.1% increase in patient volumes. The remaining 6.5% of growth came from strategic adjustments in product mix and pricing. Reported EBITDA stood at INR 71.6 crores, marking a 9.4% year-on-year growth, with an EBITDA margin of 22.2%. PAT for the quarter increased by 15% year-on-year to INR 31.5 crores, achieving a 9.8% PAT margin. For the nine months ended December, revenue increased by 12.5% and EBITDA grew 17.8% to INR 241.3 crores, with a 24.5% margin.

The B2C portfolio continued its strong momentum, achieving 8 consecutive quarters of steady growth. In Q3 FY25, B2C revenue grew 15% year-on-year to INR 178 crores, now accounting for 55% of total revenue, an improvement of 200 basis points from the previous year. This growth was led by TruHealth and Specialty testing, which grew 25% and 20% respectively. Maharashtra, a key market, saw B2C segment growth of 16% year-on-year, highlighting the strength of the brand and customer loyalty. The company aims to increase B2C contribution by 8-10% in the next 2-3 years.

Metropolis is set to finalize the acquisition of Core Diagnostics by the end of February 2025, with Core expected to contribute to revenue starting March FY25. The acquisition, valued at approximately INR 135 crores in internal cash plus a stock swap, is a major milestone to reinforce leadership in high-end specialty diagnostics. A steering committee has been established to ensure smooth integration, focusing on restructuring, talent retention, operational efficiencies, IT system integration, and cross-selling opportunities. While the acquisition is expected to be EPS accretive from year one, it will temporarily dilute group margins for the first 12 months, with margin parity targeted in 2-3 years.

Beyond Core Diagnostics, Metropolis is actively pursuing additional inorganic growth opportunities, particularly in northern markets, with several potential targets currently under consideration. The strategy focuses on acquiring local labs that possess strong brand recognition and deep consumer connections within their regions. These bolt-on acquisitions are characterized by high EBITDA, ROCE, and OCF ratios, and are expected to create substantial long-term value by leveraging Metropolis' brand leadership and capabilities to scale their operations and drive sustainable growth.

To address market challenges^🌐 and opportunities, Metropolis has implemented region-specific micro-marketing strategies. These include customized market-relevant price rationalization, revamped partner models for increased engagement, efficiency improvements in logistics, and tailored test menus for unique regional demands. Additionally, customer-centric initiatives such as integrated testing packages, home-based ECG services, and the AI-powered MedAdvisor recommendation engine have been launched. These strategies are expected to deliver a positive 2% increase in overall revenues starting Q4 FY25.

In Q3, Metropolis added 7 new labs and 125 collection centers, expanding its presence to over 750 towns. The aggressive lab expansion phase is expected to conclude by FY25/26, with future focus shifting to accelerating collection center additions rather than new labs. The company aims to improve the collection center to lab ratio to 30:1 within the next two years, which is expected to enhance operating leverage and profitability. Technology upgrades, including a new mobile app with personalized health dashboards and AI-driven recommendations, are also enhancing operational efficiency and customer experience.

Q3 FY25 presented challenges due to a surprisingly low volume of acute patients, which impacted overall diagnostic volumes and margins, as Metropolis' business is predominantly acute. This trend was considered a temporary seasonal fluctuation, with early indicators suggesting a rebound in Q4. The Q3 EBITDA margin of 22.2% was also impacted by additional costs from accelerated lab expansion, with 13-14 new labs coming online in Q3 and Q4, incurring costs before corresponding revenues materialize. Management expects a return to the 9M EBITDA margin trend of 24.5% in Q4.